Physician profile
Hussein Ajrouche
NPI 1073675427
$7,380.64
in general payments reported to CMS, 2019-2025
51 companies · $1,057 in 2025
The $1,057 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,009 · 2020: $458 · 2021: $1,039 · 2022: $1,791 · 2023: $1,187 · 2024: $840 · 2025: $1,057.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,084.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,083.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $877.93 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $721.79 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $717.24 | 2019-2025 | Vraylar, Linzess, Creon |
| Ironwood Pharmaceuticals, INC | $627.67 | 2019-2024 | Linzess |
| Pfizer INC. | $503.53 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $414.12 | 2019-2025 | Jardiance, Stiolto Respimat |
| Merck Sharp & Dohme LLC | $361.74 | 2019-2025 | Verquvo, Dificid, Capvaxive |
| Lilly USA, LLC | $327.85 | 2019-2025 | Mounjaro, Jardiance, Kisunla |
| Amgen INC. | $273.27 | 2019-2025 | Otezla, Repatha, Evenity |
| Sumitomo Pharma America, INC. | $233.84 | 2023-2025 | Gemtesa |
| Novo Nordisk INC | $218.55 | 2019-2023 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $191.44 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $183.54 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $177.36 | 2019-2025 | Xifaxan |
| Exact Sciences Corporation | $117.83 | 2023-2025 | Cologuard Collection Kit |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hussein Ajrouche listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.